These results suggest that high MFAP2 expression in gliomas plays a pivotal role in immunosuppression and that targeting MFAP2 is a potential therapeutic strategy to improve the outcome of immunotherapy. The gene discussed is MFAP2; the disease is central nervous system cancer.